DME (psychedelic)

From Wikipedia, the free encyclopedia
Jump to navigation Jump to search
DME
DME (psychedelic).png
DME-3d-sticks.png
Names
IUPAC name
2-Amino-1-(3,4-dimethoxy-phenyl)-ethanol
Other names
3,4-Dimethoxy-beta-hydroxyphenethylamine
3,4-Dimethoxy-1-ethyl-(beta-hydroxy)amine
Identifiers
3D model (JSmol)
ChemSpider
Properties
C10H15NO3
Molar mass 197.234 g·mol−1
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
☑Y verify (what is ☑Y☒N ?)
Infobox references

DME (3,4-dimethoxy-beta-hydroxyphenethylamine) is a lesser-known psychedelic drug. It is the beta-hydroxy derivative of 3,4-dimethoxyphenethylamine. DME was first synthesized by Alexander Shulgin. In his book PiHKAL, the minimum dosage is listed as 115 mg, and the duration unknown. DME produces few to no effects.[1] Very little data exists about the pharmacological properties, metabolism, and toxicity of DME.

Legality[edit]

United Kingdom[edit]

This substance is a Class A drug in the Drugs controlled by the UK Misuse of Drugs Act.[2]

See also[edit]

References[edit]

  1. ^ DME Entry in PiHKAL
  2. ^ "UK Misuse of Drugs act 2001 Amendment summary". Isomer Design. Retrieved 12 March 2014.